Product logins

Find logins to all Clarivate products below.


Human Immunodeficiency Virus (HIV) | Pharmacor | G7 | 2015

Last Updated 18 December 2015
The HIV therapy market is very dynamic. Over the last decade, many effective antiretroviral (ARV) therapies have been introduced, prompting changes in treatment guidelines and clinical practices. In particular, highly effective and safe agents called integrase strand transfer inhibitors (InSTIs) recently launched for HIV and have quickly become the standard of care for treatment-naive patients, displacing the well-entrenched single-tablet regimen (STR) Atripla. Over the next ten years, the HIV market will grow as a result of continued uptake of premium-priced STRs, including ViiV’s Triumeq (dolutegravir/abacavir/lamivudine) and Gilead’s Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate [TDF]) and Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide [TAF]), despite the current and future availability of generic formulations of individual regimen components. Furthermore, the suite of TAF-containing regimens will drive market growth as physicians turn to these regimens rather than the less-safe TDF-based therapies.

Related Market Assessment Reports

Report
Rheumatoid Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Rheumatoid Arthritis (US)
The treatment of rheumatoid arthritis (RA) typically begins with cost-effective conventional DMARDs (cDMARDs) such as methotrexate or hydroxychloroquine. For patients who fail cDMARD treatment or…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Reduced Ejection Fraction (US)
Drug treatment of heart failure with reduced ejection fraction (HFrEF) is well established, backed by a wealth of supporting evidence from clinical trials. RAAS inhibitors and beta blockers are the…
Report
Immune Thrombocytopenic Purpura – Current treatment – Treatment Algorithms: Claims Data Analysis – Immune Thrombocytopenic Purpura (US)
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by a low platelet count, resulting in an increased risk of bleeding. Current therapies for ITP can be largely divided…
Report
Migraine – Current Treatment – Treatment Algorithms: Claims Data Analysis – Migraine Prophylaxis (US)
Migraine is a neurological condition characterized by moderate to severe headaches; it can have a major impact on patients’ quality of life. Our quantitative analysis of treatment patterns…
Report
Primary Biliary Cholangitis – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Primary biliary cholangitis (PBC) is a rare autoimmune liver disease, characterized by inflammation and progressive damage leading to destruction of interlobular bile ducts, followed by cholestasis…